Almac expands neo-antigen peptide manufacturing
Almac Group, a contract development and manufacturing organization (CDMO), added a second stream for high throughput good manufacturing practice (GMP) peptide manufacture to its facility in Edinburgh, Scotland. The site manufactures neo-antigen derived peptides for the production of its individualized cancer vaccines, NeoPeptides.
The Edinburgh facility, according to the company, has a track record of high-speed peptide manufacturing, and its second line has been built upon these standards of speed. A recent increase in demand for Almac’s peptides served as the driving force behind developing a second GMP manufacturing line.
Charles Shields, vice president of peptides and small molecule active pharmaceutical ingredient (API) division, stated in a press release, that the company’s expansion is a reflection of its market understanding and its intention to maintain its worldwide supply position.
Over 80 GMP peptides were manufactured and released by the company in the first eight weeks of GMP operation at the facility, according to Almac.
Shields added that further developments of the facility and in service offerings are forthcoming.
Almac also recently worked on its supply position after expanding its commercial packaging capabilities – following demand for more sterile biological products on the market.
